文献速递白血病

达沙替尼与那韦克拉协同靶向NUP98-NSD1+/FLT3-ITD+急性髓系白血病

Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia.
PubMed 文献 · Leukemia · 2018-12-19

研究用300余种化合物筛选患者细胞和工程化细胞模型,发现共表达NUP98-NSD1与FLT3-ITD的小鼠造血祖细胞对FLT3和MEK抑制剂敏感性显著增高(P < 0.001),仅表达NUP98-NSD1的细胞对BCL2抑制剂敏感性显著增高(P = 0.029)。NUP98-NSD1+/FLT3-ITD+患者细胞对BCL2抑制剂那韦克拉敏感,但最高选择性敏感性见于SRC/ABL抑制剂达沙替尼(平均IC50 = 2.2 nM)。达沙替尼与那韦克拉在该亚型细胞中高度协同,基因表达分析显示患者BCL2A1、FGR和LCK表达显著高于健康CD34+细胞。

要点

  • 共表达NUP98-NSD1与FLT3-ITD的小鼠造血祖细胞对FLT3和MEK抑制剂敏感性显著增高(P < 0.001)。
  • NUP98-NSD1+/FLT3-ITD+患者细胞对达沙替尼平均IC50 = 2.2 nM,为最高选择性敏感性药物。
  • 达沙替尼与那韦克拉在NUP98-NSD1+/FLT3-ITD+细胞中高度协同。

核心结论

  • 数据提示达沙替尼-那韦克拉联合可能为伴NUP98-NSD1和FLT3-ITD的AML提供临床相关治疗策略。

研究设计与样本

  • 用300余种化合物筛选患者细胞和工程化细胞模型,并以小鼠造血祖细胞比较不同基因型间的药物敏感性。

主要发现

  • 共表达NUP98-NSD1与FLT3-ITD的小鼠造血祖细胞对FLT3和MEK抑制剂敏感性较仅表达任一畸变的细胞显著增高(P < 0.001)。
  • 仅表达NUP98-NSD1的细胞对BCL2抑制剂敏感性显著增高(P = 0.029)。
  • NUP98-NSD1+/FLT3-ITD+患者细胞对那韦克拉敏感,对达沙替尼平均IC50 = 2.2 nM,米托蒽醌对NUP98-NSD1+/FLT3-ITD+ AML细胞效果最差。
  • 25个显著命中中4个在对比NUP98-NSD1-/FLT3-ITD+ AML患者时仍显著。
  • NUP98-NSD1+/FLT3-ITD+患者BCL2A1、FGR和LCK表达显著高于健康CD34+细胞。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) with co-occurring NUP98-NSD1 and FLT3-ITD is associated with unfavorable prognosis and represents a particularly challenging treatment group. To identify novel effective therapies for this AML subtype, we screened patient cells and engineered cell models with over 300 compounds. We found that mouse hematopoietic progenitors co-expressing NUP98-NSD1 and FLT3-ITD had significantly increased sensitivity to FLT3 and MEK-inhibitors compared to cells expressing either aberration alone (P < 0.001). The cells expressing NUP98-NSD1 alone had significantly increased sensitivity to BCL2-inhibitors (P = 0.029). Furthermore, NUP98-NSD1+/FLT3-ITD+ patient cells were also very sensitive to BCL2-inhibitor navitoclax, although the highest select sensitivity was found to SRC/ABL-inhibitor dasatinib (mean IC50 = 2.2 nM). Topoisomerase inhibitor mitoxantrone was the least effective drug against NUP98-NSD1+/FLT3-ITD+ AML cells. Of the 25 significant hits, four remained significant also compared to NUP98-NSD1-/FLT3-ITD+ AML patients. We found that SRC/ABL-inhibitor dasatinib is highly synergistic with BCL2-inhibitor navitoclax in NUP98-NSD1+/FLT3-ITD+ cells. Gene expression analysis supported the potential relevance of dasatinib and navitoclax by revealing significantly higher expression of BCL2A1, FGR, and LCK in NUP98-NSD1+/FLT3-ITD+ patients compared to healthy CD34+ cells. Our data suggest that dasatinib-navitoclax combination may offer a clinically relevant treatment strategy for AML with NUP98-NSD1 and concomitant FLT3-ITD.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kivioja JL, Thanasopoulou A, Kumar A, et al. Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia. Leukemia. 2018. PMID: 30568173. doi:10.1038/s41375-018-0327-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。